Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Pharmaceuticals

Delayed Japan Exchange Other stock markets 08:28:39 2024-04-22 pm EDT			5-day change	1st Jan Change
5,186 ^JPY	+0.70%		+1.07%	-2.92%

Apr. 10	Japan's Nikkei slips on caution ahead of US inflation data	RE
Mar. 29	Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	MT

Chugai Pharmaceutical : Genentech Announces FDA Emergency Use Authorization for Chugai's Actemra for Hospitalized Patients with COVID-19

June 25, 2021 at 10:01 am EDT

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on June 24 (local time) regarding the Emergency Use Authorization by the US FDA for Actemra, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of COVID-19 in hospitalized adults and children.

Genentech's Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children.

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

Latest news about Chugai Pharmaceutical Co., Ltd

Japan's Nikkei slips on caution ahead of US inflation data	Apr. 09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	Mar. 29	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	Mar. 04	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Nikkei extends record rally on pharma boost	Feb. 25	RE
Nikkei hits record high as index heavyweights advance	Feb. 25	RE
US Tech Outlook Boost Asian Stock Markets	Feb. 22	MT
Global markets live: Sanofi, ABB, Qualcomm, Roche, Shell...	Feb. 01
Chugai Pharmaceutical’s Profit Down 13% in 2023	Feb. 01	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024	Feb. 01	CI
From scandal to delisting: Toshiba's long-running crisis	Dec. 19	RE
Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 6,200 Yen From 5,400 Yen, Keeps at Buy	Dec. 14	MT
Transcript : Chugai Pharmaceutical Co., Ltd. - Pre Recorded Special Call	Nov. 27
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT
Chugai Pharmaceutical’s Attributable Profit down 13.9% in Fiscal due to One-Off Lump-Sum Settlement;Shares Shed over 2.6%	23-10-24	MT
Chugai Parent Roche Settles US Lawsuit Against Biogen Over Alleged Biosimilar Infringement	23-10-24	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023	23-10-24	CI
Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2023	23-10-24	CI
Roche, Biogen Settle US Patent Infringement Case Over Actemra Biosimilar	23-10-23	MT
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug	23-10-23	RE
Jefferies Adjusts Chugai Pharmaceutical's Price Target to 5,400 Yen From 5,200 Yen, Keeps at Buy	23-10-02	MT
Japan's Nikkei posts biggest one-day drop in a month, rate jitters weigh	23-09-28	RE
Japan's Nikkei hits one-month low on Fed's higher-for-longer rate woes	23-09-27	RE
China Profits, Central Bank Outlooks Lift Asian Stock Markets	23-09-27	MT

Chart Chugai Pharmaceutical Co., Ltd

Duration

Period

More charts

Company Profile

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Sector

Pharmaceuticals

Calendar

2024-04-23 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Chugai Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5,150 JPY

Average target price

6,090 JPY

Spread / Average Target

+18.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHUGAI PHARMACEUTICAL CO., LTD	-2.92%	52.4B
ELI LILLY AND COMPANY	+25.46%	654B
NOVO NORDISK A/S	+25.38%	552B
JOHNSON & JOHNSON	-4.86%	356B
MERCK & CO., INC.	+16.44%	319B
ABBVIE INC.	+8.34%	295B
ASTRAZENECA PLC	+6.13%	211B
NOVARTIS AG	+2.93%	206B
ROCHE HOLDING AG	-7.65%	197B
PFIZER, INC.	-8.79%	147B

Other Pharmaceuticals

Chugai Pharmaceutical Co., Ltd

Equities

4519

JP3519400000

Pharmaceuticals

Chugai Pharmaceutical : Genentech Announces FDA Emergency Use Authorization for Chugai's Actemra for Hospitalized Patients with COVID-19

EPS Revisions